Evidence map›Paper›PMID 38572087›Full record

ArticleEuropean heart journal open2024

Evaluating the effect of inequalities in oral anti-coagulant prescribing on outcomes in people with atrial fibrillation.

Ryan J Mulholland, Francesco Manca, Giorgio Ciminata, Terry J Quinn, Robert Trotter, Kevin G Pollock, Steven Lister, Claudia Geue

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?Journal of health economics and outcomes research · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ryan J MulhollandUniversity of Glasgow, Glasgow, UK.ORCID https://orcid.org/0009-0008-7250-7464
Francesco MancaUniversity of Glasgow, Glasgow, UK.
Giorgio CiminataUniversity of Glasgow, Glasgow, UK.
Terry J QuinnUniversity of Glasgow, Glasgow, UK.
Robert TrotterPfizer UK, Surrey, UK.
Kevin G PollockBristol Myers Squibb, Uxbridge, UK.ORCID https://orcid.org/0000-0001-5298-0504
Steven ListerBristol Myers Squibb, Uxbridge, UK.
Claudia GeueUniversity of Glasgow, Glasgow, UK.
University of Glasgow · GBBristol-Myers Squibb (United Kingdom) · GBPfizer (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Whilst anti-coagulation is typically recommended for thromboprophylaxis in atrial fibrillation (AF), it is often never prescribed or prematurely discontinued. The aim of this study was to evaluate the effect of inequalities in anti-coagulant prescribing by assessing stroke/systemic embolism (SSE) and bleeding risk in people with AF who continue anti-coagulation compared with those who stop transiently, permanently, or never start. Methods and results: This retrospective cohort study utilized linked Scottish healthcare data to identify adults diagnosed with AF between January 2010 and April 2016, with a CHA Conclusion: Our data suggest significant inequalities in anti-coagulation prescribing, with substantial opportunity to improve initiation and continuation. Decision-making should be patient-centred and must recognize that discontinuation or cessation is associated with considerable thromboembolic risk not offset by mitigated bleeding risk.

Indexed as

Atrial fibrillationPharmacoepidemiologyReal-world dataStroke

Identifiers

PMID38572087
PMCPMC10989660
OpenAlexW4392446527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.